The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities

Pharmaceutical Research

Volumn 16, Issue 2, 1999, Pages 272-280

  Kaus, Lydia C ^d   Gillespie, William R ^a   Hussain, Ajaz S ^b   Amidon, Gordon L ^c  

^a ICON Development Solutions   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NONE

Author keywords

Biopharmaceutic classification system; Peak concentration; Permeability

Indexed keywords

ATENOLOL; METOPROLOL; RANITIDINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG PENETRATION; DRUG SOLUBILITY; INTESTINE TRANSIT TIME; MATHEMATICAL MODEL; PRIORITY JOURNAL; STOMACH EMPTYING;

EID: 0011280557     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018836727001     Document Type: Article

References (13)

1. 1. H. Lennernas, O. Ahrenstedt, R. Hallgren, L. Knutson, M. Ryde, and L. K. Paalzow. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9:1243-1252 (1992).
2. 2. B. Lever-Trafit, M. S. Gruyer, M. Marjanovic, and R. C. Chou. Estimation of oral drug absorption in man based on intestine permeability in rats. Life Sci. 58:359-363 (1996).
3. 3. B. H. Stewart, O. H. Chan, R. Lu, E. L. Reyner, E. L. Reyner, H. L. Schmid, H. W. Hamilton, B. A. Steinbaugh, and M. D. Taylor. Comparison of intestinal permeabilities in multiple in vitro and in situ models: relationship to absorption in humans. Pharm. Res. 12:693-699 (1995).
4. 4. P. J. Sinko, G. D. Leesman, and G. L. Amidon. Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm. Res. 8:979-988 (1991).
5. 5. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420 (1995).
6. 6. Guidance for Industry - Immediate Release Solid Oral Dosage Forms. Scale-up and Post-approval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. (SUPAC-IR) (Issued November 1995 by USA Food and Drug Administration).
7. 7. Guidance for Industry - Dissolution Testing of Immediate Release Solid Oral Dosage Forms (Issued August 1997 by USA Food and Drug Administration).
8. 8. J. B. Dressman, D. Fleischer, and G. L. Amidon. Physicochemical model for dose-dependent drug absorption. J. Pharm. Sci. 73:1274-1278 (1984).
9. 9. R. L. Oberle and G. L. Amidon. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine: An explanation for the double peak phenomenon. J. Pharmacokin. Biopharm. 15:529-545 (1987).
10. 10. L. X. Yu, E. Lipka, J. R. Crison, and G. L. Amidon. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Del. Rev. 19:359-376 (1996).
11. 11. A. B. Suttle, G. M. Pollack, and K. L. R. Brouwer. Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles. Pharm. Res. 9:350-356 (1992).
12. 12. S. S. Davis, J. G. Hardy, and J. W. Fara. Transit of pharmaceutical dosage forms through the small intestine. Gut 27:886-892 (1986).
13. 13. K. M. Koch, A. F. Parr, J. J. Tomlinson, E. P. Sandefer, G. A. Digenis, K. H. Donn, and J. R. Powell. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm. Res. 10:1027-1030 (1993).